drugset / Trial / NCT03355638

Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3

NCT03355638

Phase 4 Completed 60 enrolled University of Brescia
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine whether a combination of intravitreal aflibercept and pranoprofen eyedrops or nutraceutical support provides additional benefit over IVA monotherapy for the treatment of choroidal neovascularization in age-related macular degeneration.

Timeline

Start
2016-01
Primary completion
2016-07
Completion
2017-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 0.5 mg Intravitreal
Subject Omega-3 fatty acids Unknown Oral
Subject Pranoprofen Small molecule 0.1 % Topical

Indications